Defective CKR5 Receptor Offers Immunity to AIDS


CKR5 is a recently discovered co-receptor required by strains of HIV that act early in the course of infection for entry into cells of the immune system. In addition to binding HIV, this receptor can also bind chemokines, causing HIV infection to be blocked. Scientists now have found that a mutation in the gene that codes for CKR5 consisting of a 32-base pair deletion may also block or inhibit HIV infection.

Indeed, individuals homozygous for the mutated gene allele who have been exposed to HIV or are at high risk of HIV infection have not developed AIDS. Furthermore, individuals heterozygous for the mutated allele may have some protection and may develop the disease more slowly. In one study of 1955 people, scientists found no individuals who were infected and homozygous for the mutated allele. The allele seems to be more common in Caucasian populations than in African American populations.

Treatment for AIDS involving CKR5 looks promising, as research indicates that people live perfectly well without CKR5. Therapy involving chemokines seems more risky, as unnatural levels of these chemicals can cause severe immune system complications. On the other hand, treatments that block or disable CKR5 may prove to be successful.

"New AIDS Study Reveals Startling Immunity Data" by Gina Kolata, New York Times, September 27, 1996.

[Return to What's New]


Search | How to Order | E-mail Us

Copyright ©1997 McGraw-Hill College Division